Heineken sells less beer after fraught pricing talks with retailers
The Dutch brewer saw shares dip as it also indicated that US tariffs would act as a drag on company profits.
The company, which also makes Birra Moretti and Amstel, reported a 1.2% slump in beer volumes in the first six months of 2025, driven by declines in Brazil, the US and parts of Europe.
It said European volumes dropped by 4.7% after a number of retailers, primarily in France, the Netherlands, Germany and Spain, pulled the brand due to planned price increases.
Heineken said the talks with retailer groups took longer than expected to be resolved.
Group revenues dropped by 5% to 16.9 billion euros (£14.6 billion) for the half-year.
The company said it also saw weaker sales in the US over the period, with beer volumes down by 'high' single digits due to weak consumer sentiment.
It comes as the company is set to be impacted by the proposed 15% tariff on all EU products imported into the US.
In the UK, net revenues, before exceptional items and amortisation, increased by 'low single digits' over the half.
Beers and cider volumes dropped, despite strong growth from its Cruzcampo lager brand.
Its Murphy's stout brand also saw further growth after being boosted by improved distribution and new draughts.
The brand benefited from supply issues from rival stout brand Guinness late last year following soaring demand.
Dolf van den Brink, chief executive and chairman, said: 'We continued to invest in future-proofing our business, strengthening our footprint and brand portfolios, funded by productivity savings.
'Our volume performance improved across all regions in the second quarter and continued to be of high quality.'

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
GSK Lifts Outlook As Specialty Medicines, Vaccines Fuel Growth
British pharmaceutical giant GSK Plc (NYSE:GSK) shares rose on Wednesday after reporting second-quarter results that surpassed analyst expectations and led the company to raise its full-year 2025 guidance. Driven by exceptional growth in Specialty Medicines and Vaccines, GSK's second-quarter sales reached $10.66 billion (7.98 billion British pounds), a 6% increase at constant currency, exceeding analyst estimates of $10.33 billion. Core earnings jumped 15% at constant currency to $1.24 per share (46.5 pence) outperforming the consensus forecast of $ company attributed this core earnings growth to the strong performance of its Specialty Medicines and Vaccines divisions, coupled with higher royalty income and a disciplined escalation of investment in key research and development (R&D) areas, particularly within Oncology and Vaccines. Vaccine sales jumped 5% (+9% at constant currency or cc) to 2.09 billion pounds, reflecting growth in Meningitis vaccines related to uptake following expanded recommendation and public funding of Bexsero in Europe, as well as growth in Shingrix driven by launch uptake in France and strong demand across several other European markets and Japan. Arexvy sales reached 66 million pounds, up 6% (+13% cc). Meningitis vaccine sales increased 17% (+22% cc) to 379 million, while established vaccine sales of 787 million increased 2% (+6% cc). Shingrix sales reached 853 million pounds, up 3% (+6% cc). In July, the FDA agreed to review the application to extend the indication of Arexvy (Respiratory Syncytial Virus Vaccine, Adjuvanted) to adults aged 18-49 who are at increased risk. Also in July, the FDA extended the review period for the Biologics License Application (BLA) for GSK's Blenrep combinations for relapsed or refractory multiple myeloma patients who have received at least one prior line of therapy. View more earnings on GSK Specialty Medicines sales grew by double-digit percentages (+10% and 15% cc) in the quarter to 3.33 billion pounds, reflecting continued growth across disease areas, with strong performances in HIV, Respiratory, Immunology & Inflammation, and Oncology. General Medicines sales fell by 10% (-6% cc) to 2.57 billion pounds. GSK is progressing on 14 major pipeline opportunities, each with a potential value of over 2 billion pounds, set to launch between 2025 and 2031. Phase 3 study for tebipenem, a new antibiotic for complicated urinary tract infections, was stopped early because it worked so well. The company plans to file for approval by the end of the year. Phase 3 development for depemokimab, aimed at treating COPD, has begun with the launch of the ENDURA study program. Key trials expected to begin in the second half of 2025 include GSK'227, a B7H3-targeting antibody-drug conjugate for small cell lung cancer, GSK'981 (IDRx-42) for second-line treatment of gastrointestinal stromal tumors, Efimosfermin for MASH, and an ultra-long-acting injectable HIV treatment combining cabotegravir and rilpivirine, to be given every four months. Tariff Outlook and Guidance Addressing a broader macroeconomic concern, GSK acknowledged the U.S. Administration's initiation of an investigation under Section 232 of the Trade Expansion Act, which seeks to ascertain the potential effects of pharmaceutical product imports on national security. The company said it is well-positioned to respond to the potential financial impact of tariffs, with mitigation options identified. According to Reuters, GSK's CFO indicated an anticipation of some tariffs coming in the second half of the year, which are expected to lower the gross margin slightly. GSK raised its full-year 2025 guidance and says it includes tariffs enacted thus far and the European tariffs indicated this week. It now expects sales to increase toward the top of the 3%–5% range. Core operating profit and earnings are also expected to grow towards the top end of the 6% to 8% range. Specialty Medicine sales are expected to increase in the low teens versus prior guidance of a low double-digit percentage. Vaccine revenue is expected to decline by a low single-digit percent to broadly stable compared to the prior outlook of a decrease of low single-digit percent, and general medicine sales are expected to be broadly stable. Price Action: At last check on Wednesday, GSK stock was up 3.57% to $40.37 during the premarket session. Read Next:Photo by HJBC via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? GSK (GSK): Free Stock Analysis Report This article GSK Lifts Outlook As Specialty Medicines, Vaccines Fuel Growth originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 minutes ago
- Yahoo
HSBC's $300 Million Scandal Resurfaces -- Swiss Probe Reopens Risk for Global Bank
Swiss and French authorities have opened a new investigation into HSBC Holdings Plc's (NYSE:HSBC) Swiss private bank, reigniting concerns over legacy compliance risks that had long been buried. The probe centers on two historical client relationships, according to the bank's latest disclosure. While the details remain limited, HSBC warned investors that the potential impact on the firm could be materialthough the timing and outcome are still anyone's guess. Warning! GuruFocus has detected 6 Warning Sign with HSBC. This isn't the first time HSBC's Swiss arm has drawn regulatory heat. Just last year, Switzerland's financial regulator, Finma, found that the bank failed to perform adequate checks on politically exposed personsclients considered higher risk under anti-money laundering (AML) frameworks. Over $300 million in questionable transactions, processed between 2002 and 2015, were flagged. As a result, HSBC was ordered to tighten its AML controls and temporarily halt onboarding any new politically exposed clients. Now, with a fresh spotlight on its pastand scrutiny from two countriesHSBC's private banking business could be looking at a longer road to reputational repair. While this doesn't change the fundamentals overnight, it reopens old questions about governance and risk oversight. Investors watching from the sidelines may want to stay alert: depending on how the investigation unfolds, this story could evolve into a much bigger headline. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
39 minutes ago
- Yahoo
Report – Inter Milan Open To Greenlighting Germany Defender Transfer To Crystal Palace For €40M
Serie A giants Inter Milan reportedly plan to let Yann Bisseck join Crystal Palace in a €40 million deal this summer. According to Sky Sport via FCInterNews, the Nerazzurri are open to negotiating the German's exit. Yann Bisseck has found himself on the chopping block after Simone Inzaghi's departure. Indeed, new boss Cristian Chivu wants to revamp his defensive options ahead of the new season. Therefore, Inter have set their sights on Genoa's Koni De Winter and Parma's Giovanni Leoni. Inter Milan Open to Selling Yann Bisseck to Crystal Palace LEVERKUSEN, GERMANY – DECEMBER 10: Yann Aurel Bisseck of FC Internazionale looks on during the UEFA Champions League 2024/25 League Phase MD6 match between Bayer 04 Leverkusen and FC Internazionale Milano at BayArena on December 10, 2024 in Leverkusen, Germany. (Photo by) However, before pursuing more incoming deals, Inter must raise funds from player sales. Bisseck is on the market, largely thanks to his significant value. Indeed, the Eagers are ready to table a significant €32 million bid for the 24-year-old. Yet, Inter would like to earn more. Particularly, they would sanction Bisseck's exit for a fee in the region of €40 million. Bisseck's departure would hand the Nerazzurri much-needed funds and enable them to pursue De Winter or Leoni. It's now up to Palace to decide whether they want to spend that much.